Multiple Sclerosis, Relapsing-RemittingNCT06129019
the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis
A study testing Reiki in people with Multiple Sclerosis, Relapsing-Remitting, run by Ataturk University at 1 site in Turkey (Türkiye).
Trial summary
During Reiki application, individuals may report feeling a slight warm sensation under and near the therapist's hand. The only rule in Reiki practice is that the individual must give permission to the practitioner to facilitate the flow of energy. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Multiple Sclerosis, Relapsing-Remitting
- What is being tested?
- Reiki
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2023to 1 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Being over 18 years of age
- Having the ability to use technological devices
- Not using Reiki and similar integrative treatment methods
- No verbal communication disability (hearing and speaking)
- Not having a diagnosed psychiatric disorder
- Patients who have been receiving Relapsing-Remitting MS treatment for more than three months
Who cannot join
- Patients using any complementary alternative treatment methods
- Patients who cannot communicate by phone to participate in remote reiki application
- Patients with autoimmune diseases other than multiple sclerosis
- Patients with communication disabilities
- Patients with another known neurological system disease (dementia, Alzheimer's, etc.).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Investigation of the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Individuals Diagnosed With Relapsing-Remitting Multiple Sclerosis
During Reiki application, individuals may report feeling a slight warm sensation under and near the therapist's hand. The only rule in Reiki practice is that the individual must give permission to the practitioner to facilitate the flow of energy. The person receiving Reiki during the application does not have to believe in Reiki. Because Reiki is universal life energy and is available to everyone. Reiki is generally safe and no serious side effects have been reported. Reiki practice in the last 10 years; It is increasing among physicians, nurses and other healthcare professionals.
This study was planned to investigate the effect of reiki application on depression, anxiety and physical activity in individuals diagnosed with Relapsing-Remitting Multiple Sclerosis.
Geri bildirim gönder Yan paneller
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Being tested
- Reiki
- Keywords
- reiki, anxiety, physical activity
- Medical subject headings
- Multiple Sclerosis, Relapsing-Remitting, Anxiety Disorders, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ReikiBehavioural
Reiki application will be done
| Study group | Role | What they receive |
|---|---|---|
| Experimental: | Experimental | Reiki application will be done Receives: Behavioral: Reiki |
| Control | No intervention | Reiki application will not be done |
What is being measured
The primary outcome is the main question the study is designed to answer.
Beck Depression Scale
The scale was administered to investigate each participant's feelings and attitudes regarding the general depressive state. Each patient was asked to read several groups of statements and then mark the one statement in each group that best described how he or she felt "during the past week." BDI, which evaluates four statements describing increasing intensities of depressive symptoms between 0 and 3 points, includes 21 items. Depressive symptoms were classified as follows: minimal-to-moderate depressive symptoms (range 14 to 19), moderate-to-severe depressive symptoms (range 20 to 29), severe depressive symptoms (range 30 to 63).
Measured: 4 week
Beck Anxiety Scale
BAI is a self-rating scale developed by Beck et al. (1988) and used to determine the frequency of anxiety symptoms experienced by individuals. It is a Likert-type scale consisting of 21 items and scored between 0-3. Its validity and reliability in Turkey were determined by Ulusoy et al.
Measured: 4 week
International Physical Activity Survey
There are some scales that can be used in primary care to evaluate physical mobility. One of these is the "International Physical Activity Questionnaire", which was developed by the International Consensus Group consisting of researchers from various countries with the support of the World Health Organization and the Center for Disease Control, to be used to measure physical activity and inactivity in 1997 and 1998; (IPAQ)" is a standard tool. Reliability and/or validity studies were conducted in 14 centers from 12 countries in 2000 for at least two of the four long (IPAQ-long) and four short (IPAQ-SF) forms of the IPAQ. This scale was adapted into Turkish as long form (UF) and short form (SF) under the name "International Physical Activity Questionnaire (UFAA)" and its validity and reliability study was conducted by Sağlam et al. in 2010
Measured: 4 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2023
- Study start1 Jun 2023
- Primary completion1 Apr 2024
- Study completion1 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple Sclerosis, Relapsing-RemittingStudies of the same condition, open and under way.
- More trials run by Ataturk UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ataturk University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gülcan Bahçecioğlu Turan, Ataturk University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06129019
- Sponsor's protocol ID
- 22/11
- Status last verified
- Jan 2025
- First submitted
- 8 Nov 2023
- Last updated
- 7 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Individuals Diagnosed With Relapsing-Remitting Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT06129019
- Acronym / sponsor ID
- 22/11
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Keywords
- reiki, anxiety, physical activity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Ataturk UniversityUniversity, hospital or other
- Study start
- 1 Jun 2023 (actual)
- Primary completion
- 1 Apr 2024 (actual)
- Study completion
- 1 Jun 2024 (actual)
- First posted
- 13 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
During Reiki application, individuals may report feeling a slight warm sensation under and near the therapist's hand. The only rule in Reiki practice is that the individual must give permission to the practitioner to facilitate the flow of energy. The person receiving Reiki during the application does not have to believe in Reiki. Because Reiki is universal life energy and is available to everyone. Reiki is generally safe and no serious side effects have been reported. Reiki practice in the last 10 years; It is increasing among physicians, nurses and other healthcare professionals.
This study was planned to investigate the effect of reiki application on depression, anxiety and physical activity in individuals diagnosed with Relapsing-Remitting Multiple Sclerosis.
Geri bildirim gönder Yan paneller
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental: | Experimental | Behavioral: ReikiReiki application will be done |
| Control | No intervention | –Reiki application will not be done |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Being over 18 years of age
- Having the ability to use technological devices
- Not using Reiki and similar integrative treatment methods
- No verbal communication disability (hearing and speaking)
- Not having a diagnosed psychiatric disorder
Key exclusion criteria (5 listed)
- Patients using any complementary alternative treatment methods
- Patients who cannot communicate by phone to participate in remote reiki application
- Patients with autoimmune diseases other than multiple sclerosis
- Patients with communication disabilities
- Patients with another known neurological system disease (dementia, Alzheimer's, etc.).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ReikiReiki application will be done | Behavioural | Experimental: |
Primary outcome
Beck Depression Scale
Time frame: 4 week
The scale was administered to investigate each participant's feelings and attitudes regarding the general depressive state. Each patient was asked to read several groups of statements and then mark the one statement in each group that best described how he or she felt "during the past week." BDI, which evaluates four statements describing increasing intensities of depressive symptoms between 0 and 3 points, includes 21 items. Depressive symptoms were classified as follows: minimal-to-moderate depressive symptoms (range 14 to 19), moderate-to-severe depressive symptoms (range 20 to 29), severe depressive symptoms (range 30 to 63).
Beck Anxiety Scale
Time frame: 4 week
BAI is a self-rating scale developed by Beck et al. (1988) and used to determine the frequency of anxiety symptoms experienced by individuals. It is a Likert-type scale consisting of 21 items and scored between 0-3. Its validity and reliability in Turkey were determined by Ulusoy et al.
International Physical Activity Survey
Time frame: 4 week
There are some scales that can be used in primary care to evaluate physical mobility. One of these is the "International Physical Activity Questionnaire", which was developed by the International Consensus Group consisting of researchers from various countries with the support of the World Health Organization and the Center for Disease Control, to be used to measure physical activity and inactivity in 1997 and 1998; (IPAQ)" is a standard tool. Reliability and/or validity studies were conducted in 14 centers from 12 countries in 2000 for at least two of the four long (IPAQ-long) and four short (IPAQ-SF) forms of the IPAQ. This scale was adapted into Turkish as long form (UF) and short form (SF) under the name "International Physical Activity Questionnaire (UFAA)" and its validity and reliability study was conducted by Sağlam et al. in 2010
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis, Relapsing-Remitting
Active, not recruiting
Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting
Recruiting
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
Multiple Sclerosis (MS) - Relapsing-remitting
Recruiting
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Not yet recruiting
Treatment of Memory Retrieval Impairments in MS With HDtDCS to the LIFG in a Placebo Controlled Trial
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)
Active, not recruitingPhase 4
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Reiki in people with Multiple Sclerosis, Relapsing-Remitting, run by Ataturk University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Beck Depression Scale (time frame: 4 week). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2025; AzTrials last refreshed its copy on 7 Nov 2026.